AstraZeneca Shares Decline 7 Percent Amid Bristol Myers Squibb Acquisition Discussions

Shares in AstraZeneca PLC fell 7% to 11,723 pence on Monday following reports that the British pharmaceutical giant has entered discussions to acquire its American counterpart, Bristol Myers Squibb Co. The potential transaction would establish a pharmaceutical entity valued at approximately $400 billion, positioning it as the fourth-largest company in the sector by market capitalisation.

The negative response from London investors underscores the magnitude of the proposed transaction. AstraZeneca, headquartered in Cambridge, represents the second-largest listed company in the United Kingdom with a market capitalisation approaching £196 billion. Bristol Myers Squibb, based in Princeton, New Jersey, and recognised primarily for its oncology treatments, commands a market value of $133 billion.

According to sources familiar with the matter, discussions have taken place over recent months, though no certainty exists regarding the successful conclusion of a deal. AstraZeneca has declined to provide comment on the reports.

The acquisition would significantly expand AstraZeneca’s footprint in the United States, where the company has already pledged $50 billion towards research and manufacturing initiatives through 2030. The transaction would also represent a notable strategic shift for Pascal Soriot, the chief executive who successfully defended against a hostile £70 billion takeover attempt by Pfizer in 2014 before rebuilding AstraZeneca’s development pipeline with a focus on cancer immunotherapies, which harness the body’s immune system to combat tumours.

The recovery orchestrated by Soriot transformed AstraZeneca into a British corporate achievement and established him as one of the longest-tenured chief executives within the FTSE 100 index. Last week, he reiterated the company’s confidence in achieving its target of $80 billion in annual sales by 2030, compared with $59 billion recorded last year. This assertion came despite the unexpected clinical failure of Wainua, a prominent cardiovascular drug candidate in the development pipeline.

During the same update, Soriot encouraged Western pharmaceutical manufacturers to operate at what he termed “Chinese speed” to prevent falling behind competitors in the global market.

Bristol Myers Squibb has demonstrated its own operational strength, surpassing Wall Street projections with second-quarter revenues of $12.97 billion, representing a 5% increase on a constant currency basis. The company subsequently raised its full-year guidance. Bristol Myers Squibb maintains its United Kingdom research operations in Moreton on the Wirral, with a commercial headquarters located in Uxbridge.